

Zydus depressive disorder generic gets approval in China

Venlafaxine is indicated for the treatment of Major Depressive Disorder (MDD), Generalised Anxiety Disorder (GAD), Social Anxiety Disorder (SAD), and Panic Disorder (PD)



Ahmedabad: Zydus Lifesciences has received marketing approval from the National Medical Products Administration (NMPA) of China for Venlafaxine Extended-Release (ER) capsules.

Venlafaxine is indicated for the treatment of Major Depressive Disorder (MDD), Generalised Anxiety Disorder (GAD), Social Anxiety Disorder (SAD), and Panic Disorder (PD).

They help restore the balance of serotonin and norepinephrine in the brain to improve mood and reduce anxiety.

This is Zydus's first approval in China, and the capsules will be produced at its Moraiya, Ahmedabad-based facility.

News Source:

<https://pharma.economictimes.indiatimes.com/news/drug-approvals-and-launches/zydus-depressive-disorder-generic-gets-approval-in-china/125249088>